These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Reich DS; Arnold DL; Vermersch P; Bar-Or A; Fox RJ; Matta A; Turner T; Wallström E; Zhang X; Mareš M; Khabirov FA; Traboulsee A; Lancet Neurol; 2021 Sep; 20(9):729-738. PubMed ID: 34418400 [TBL] [Abstract][Full Text] [Related]
26. Study protocol for a randomised, double-blind, placebo-controlled study evaluating the Efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial. Urbi B; Broadley S; Bedlack R; Russo E; Sabet A BMJ Open; 2019 Nov; 9(11):e029449. PubMed ID: 31719072 [TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M; Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398 [TBL] [Abstract][Full Text] [Related]
28. Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study. Lauria G; Dalla Bella E; Antonini G; Borghero G; Capasso M; Caponnetto C; Chiò A; Corbo M; Eleopra R; Fazio R; Filosto M; Giannini F; Granieri E; La Bella V; Logroscino G; Mandrioli J; Mazzini L; Monsurrò MR; Mora G; Pietrini V; Quatrale R; Rizzi R; Salvi F; Siciliano G; Sorarù G; Volanti P; Tramacere I; Filippini G; J Neurol Neurosurg Psychiatry; 2015 Aug; 86(8):879-86. PubMed ID: 25595151 [TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD; Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767 [TBL] [Abstract][Full Text] [Related]
30. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169 [TBL] [Abstract][Full Text] [Related]
31. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Lenglet T; Lacomblez L; Abitbol JL; Ludolph A; Mora JS; Robberecht W; Shaw PJ; Pruss RM; Cuvier V; Meininger V; Eur J Neurol; 2014 Mar; 21(3):529-36. PubMed ID: 24447620 [TBL] [Abstract][Full Text] [Related]
32. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442 [TBL] [Abstract][Full Text] [Related]
33. Arimoclomol, a coinducer of heat shock proteins for the potential treatment of amyotrophic lateral sclerosis. Phukan J IDrugs; 2010 Jul; 13(7):482-96. PubMed ID: 20582873 [TBL] [Abstract][Full Text] [Related]